Amylyx Pharmaceuticals, Inc. Basic Shares Outstanding (Weighted Average)
Amylyx Pharmaceuticals, Inc. (AMLX) reported Basic Shares Outstanding (Weighted Average) of 111.20 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-06
- Amylyx Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 111.20M shares, a 24.75% increase year-over-year.
- Amylyx Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 110.56M shares, a 29.02% increase year-over-year.
- Amylyx Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 110.01M shares, a 60.37% increase year-over-year.
- Amylyx Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 93.33M shares, a 37.07% increase year-over-year.
- Amylyx Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 94.57M shares, a 38.78% increase from fiscal 2024.
- Amylyx Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 68.14M shares, a 1.35% increase from fiscal 2023.
- Amylyx Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 67.23M shares, a 14.94% increase from fiscal 2022.
- Amylyx Pharmaceuticals, Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 58.50M shares, a 788.13% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 111.20M shares 10-Q · filed 2026-08-06 | 110.88M shares 10-Q · filed 2026-08-06 | 110.59M shares derived: average of 3 quarters · filed 2026-08-06 | 106.28M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 110.56M shares 10-Q · filed 2026-05-07 | 110.29M shares derived: average of 2 quarters · filed 2026-05-07 | 104.64M shares derived: average of 3 quarters · filed 2026-05-07 | 100.76M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | 110.01M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | 101.67M shares derived: average of 2 quarters · filed 2026-03-03 | 97.49M shares derived: average of 3 quarters · filed 2026-08-06 | 94.57M shares 10-K · filed 2026-03-03 |
| 2025-09-30 | 93.33M shares 10-Q · filed 2025-11-06 | 91.24M shares derived: average of 2 quarters · filed 2026-08-06 | 89.42M shares 10-Q · filed 2025-11-06 | 84.19M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | 89.14M shares 10-Q · filed 2026-08-06 | 87.43M shares 10-Q · filed 2026-08-06 | 81.14M shares derived: average of 3 quarters · filed 2026-08-06 | 77.88M shares derived: average of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | 85.70M shares 10-Q · filed 2026-05-07 | 77.15M shares derived: average of 2 quarters · filed 2026-05-07 | 74.13M shares derived: average of 3 quarters · filed 2026-05-07 | 72.60M shares derived: average of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | 68.60M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | 68.34M shares derived: average of 2 quarters · filed 2026-03-03 | 68.24M shares derived: average of 3 quarters · filed 2026-03-03 | 68.14M shares 10-K · filed 2026-03-03 |
| 2024-09-30 | 68.09M shares 10-Q · filed 2025-11-06 | 68.06M shares derived: average of 2 quarters · filed 2025-11-06 | 67.99M shares 10-Q · filed 2025-11-06 | 67.88M shares derived: average of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | 68.02M shares 10-Q · filed 2025-08-07 | 67.94M shares 10-Q · filed 2025-08-07 | 67.81M shares derived: average of 3 quarters · filed 2025-08-07 | 67.71M shares derived: average of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | 67.85M shares 10-Q · filed 2025-05-08 | 67.71M shares derived: average of 2 quarters · filed 2025-05-08 | 67.61M shares derived: average of 3 quarters · filed 2025-05-08 | 67.52M shares derived: average of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | 67.56M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | 67.49M shares derived: average of 2 quarters · filed 2025-03-04 | 67.40M shares derived: average of 3 quarters · filed 2025-03-04 | 67.23M shares 10-K · filed 2025-03-04 |
| 2023-09-30 | 67.41M shares 10-Q · filed 2024-11-07 | 67.32M shares derived: average of 2 quarters · filed 2024-11-07 | 67.12M shares 10-Q · filed 2024-11-07 | 66.71M shares derived: average of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | 67.23M shares 10-Q · filed 2024-08-08 | 66.98M shares 10-Q · filed 2024-08-08 | 66.48M shares derived: average of 3 quarters · filed 2024-08-08 | 64.49M shares derived: average of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | 66.72M shares 10-Q · filed 2024-05-09 | 66.11M shares derived: average of 2 quarters · filed 2024-05-09 | 63.58M shares derived: average of 3 quarters · filed 2024-05-09 | 62.25M shares derived: average of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | 65.49M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | 62.01M shares derived: average of 2 quarters · filed 2024-02-22 | 60.77M shares derived: average of 3 quarters · filed 2024-02-22 | 58.50M shares 10-K · filed 2024-02-22 |
| 2022-09-30 | 58.53M shares 10-Q · filed 2023-11-09 | 58.40M shares derived: average of 2 quarters · filed 2023-11-09 | 56.16M shares 10-Q · filed 2023-11-09 | 43.83M shares derived: average of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | 58.28M shares 10-Q · filed 2023-08-10 | 54.96M shares 10-Q · filed 2023-08-10 | 38.93M shares derived: average of 3 quarters · filed 2024-02-22 | 30.89M shares derived: average of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | 51.60M shares 10-Q · filed 2023-05-11 | 29.26M shares derived: average of 2 quarters · filed 2024-02-22 | 21.76M shares derived: average of 3 quarters · filed 2024-02-22 | 17.93M shares derived: average of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | 6.91M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | 6.84M shares derived: average of 2 quarters · filed 2024-02-22 | 6.70M shares derived: average of 3 quarters · filed 2024-02-22 | 6.59M shares 10-K · filed 2024-02-22 |
| 2021-09-30 | 6.76M shares 10-Q · filed 2022-11-10 | 6.60M shares derived: average of 2 quarters · filed 2022-11-10 | 6.48M shares 10-Q · filed 2022-11-10 | |
| 2021-06-30 | 6.43M shares 10-Q · filed 2022-08-11 | 6.33M shares 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |